Expanse Medical, Inc. appears in FDA device records as the applicant behind the FLOWRUNNER Aspiration System, filed under product code QEZ and regulation number 870.5150, the embolectomy catheter classification. The supplied collection contains one linked 510(k) record, K262864, decided October 26, 2026 as substantially equivalent, and that single record carries the SESE decision in both the full collection and the smaller record sample. The filings describe a catheter family rather than a single SKU, with named configurations and guide wire compatibility listed in the review correspondence. [1][2][3]
The October 2026 clearance
K262864 was received August 14, 2026 and decided October 26, 2026 with decision code SESE, described as substantially equivalent, under traditional clearance with no third-party review. The record lists the applicant as Expanse Medical, Inc. at 7060 Koll Center Pkwy., Suite 300, Pleasanton, CA, with Shiva Ardakani as contact, and names the device FLOWRUNNER Aspiration System. The advisory committee is recorded as cardiovascular, and the submission included a summary rather than only a statement. [1]
The corresponding premarket notification entry for K262864 shows a control plan authorized field marked no and a page update date of November 9, 2026. That page supplies administrative context for the same submission number rather than separate product detail. [2]
Earlier FLOWRUNNER submissions
A March 20, 2026 substantial-equivalence determination letter addressed to Expanse Medical, Inc. covers K254208, trade name FLOWRUNNER Aspiration System, under regulation 21 CFR 870.5150, embolectomy catheter, Class II, product codes QEZ and KRA. The letter states the device was dated December 22, 2025 and received December 29, 2025, and concludes the FLOWRUNNER Aspiration System family is substantially equivalent to the predicate device FLOWRUNNER across intended use, design, materials, packaging, fundamental scientific technology, manufacturing, performance specifications and sterilization. [3]
A July 14, 2025 letter to Expanse Medical Inc. covers K251488, also FLOWRUNNER Aspiration System, under the same regulation and product codes, dated and received June 18, 2025. Its comparison table sets the Expanse ICE Aspiration System against the Expanse FLOWRUNNER Aspiration System on indication for use, materials, packaging, sterilization and biocompatibility, with the indication described as removal of fresh, soft emboli and thrombi from vessels of the peripheral arterial and venous systems. [5]
A product-code query for QEZ limited to the expanse applicant returns a total of three results, including K251488 with a special clearance type and a substantially equivalent decision description. That count reflects the query result set, not a company-wide filing total. [7]
Documented configurations and labeling
The K254208 correspondence lists guide wire compatibility by configuration: 14F with 0.035 inch, 12F with 0.035 inch, 7F with 0.014 inch, and SP 7F with 0.014 inch, alongside catheter outer diameter entries. These are the named size variants appearing in the review record. [3]
AccessGUDID holds a device record for the FLOWRUNNER 14F Aspiration System, 100cm, under identifier 00860011713180, with a record history entry. The listing documents that specific configuration in the UDI database. [6]
Applicant, brand and corporate statements
Expanse Medical's own site states that FlowPhysix was incubated in 2022 and spun off from Expanse Medical in April 2024, and that FlowPhysix is commercializing the FLOWRUNNER Aspiration System in the US and select global geographies after 510(k) clearance and first-in-human cases. Those are the publisher's statements; the FDA filings name Expanse Medical, Inc. as applicant. [4]
FlowPhysix's company page describes the FLOWRUNNER Aspiration System as developed from fluid-flow science and clot morphology studies, and gives an Austin, TX address with an indication for removal of fresh, soft emboli and thrombi from peripheral vessels, pointing to instructions for use LBL024. Corporate descriptions of performance come from that publisher, not from the FDA record. [8]


